Trial Profile
An observational, multi centre, Italian, retrospective, real World evidence cohort study describing one and two year Annualized Relapse Rate (ARR) and proportion of patients with No Evidene of Disease Activity (NEDA-3) in patients treated with Fingolimod
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2021
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms GENIUS
- 14 Nov 2018 Preliminary results (n=391) assessing Annualized Relapse rate (ARR) and the proportion of patients with No Evidence of Disease Activity (NEDA-3) after 1 and 2 years of treatment, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 24 May 2018 New trial record
- 23 May 2018 Preliminary results (n=391) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research